Insider Trading January 28, 2026

Intuitive Surgical Director Sells $14.48M in Stock as Company Posts Strong Q4 Results

Director Gary S. Guthart executed share sales and option exercises under a 10b5-1 plan as analysts respond to better-than-expected quarterly performance

By Jordan Park ISRG
Intuitive Surgical Director Sells $14.48M in Stock as Company Posts Strong Q4 Results
ISRG

Intuitive Surgical director Gary S. Guthart sold 27,300 shares on January 27, 2026, receiving $14,475,672, and on the same day exercised options to acquire 25,500 shares at $174.2567 per share. The trades were carried out under a pre-set SEC Rule 10b5-1 plan that expires April 28, 2026. The company reported robust fourth-quarter 2025 results with $2.87 billion in revenue, exceeding several analyst forecasts and prompting multiple firm upgrades and reiterated Buy ratings.

Key Points

  • Director Gary S. Guthart sold 27,300 shares on January 27, 2026, for $14,475,672 in multiple transactions priced between $530.0981 and $531.5285.
  • Guthart also exercised options to acquire 25,500 shares at $174.2567 on the same day, representing $4,443,545 in value; both actions were executed under a 10b5-1 plan expiring April 28, 2026.
  • Intuitive Surgical reported Q4 2025 revenue of $2.87 billion, a 19% increase year-over-year, beating Stifel and consensus estimates and prompting several analyst upgrades and reiterated Buy ratings.

Transaction details

Gary S. Guthart, who serves on the board of Intuitive Surgical Inc (NASDAQ:ISRG), disposed of 27,300 shares of the company's common stock on January 27, 2026. The sales were completed in multiple tranches at prices spanning from $530.0981 to $531.5285, resulting in aggregate proceeds of $14,475,672.

Concurrent option exercise

On the same date, Guthart exercised stock options to obtain 25,500 shares of Intuitive Surgical common stock at an exercise price of $174.2567 per share, representing a total notional value of $4,443,545. Both the sales and the option exercise were implemented through a pre-arranged trading program compliant with SEC Rule 10b5-1. That plan is scheduled to lapse on April 28, 2026.

Quarterly performance and guidance highlights

Intuitive Surgical posted fourth-quarter 2025 revenue of $2.87 billion, a year-over-year increase of 19%, a result that topped Stifel and consensus estimates of $2.72 billion. According to commentary within analyst notes, the company beat expectations on earnings per share and revenue by roughly 11% and 4%, respectively, as observed by RBC Capital. Guidance for gross margins in 2026 was noted by Truist Securities to reflect a 90 basis point improvement compared with the prior year.

Analyst reactions

Market analysts responded to the quarterly results and company commentary with a string of positive ratings and target revisions. TD Cowen initiated coverage with a Buy rating and a $660.00 price target, identifying Intuitive Surgical as a core holding in MedTech. Freedom Capital Markets upgraded its view from Hold to Buy and set a $610.00 target, attributing its move in part to expectations tied to the da Vinci 5 surgical system rollout. Stifel and Truist Securities both maintained Buy ratings with respective price targets of $670.00 and $650.00. RBC Capital kept an Outperform rating with a $650.00 target following the quarter it described as robust.

Context and close

The insider sales and option exercise occurred alongside a quarterly report that outperformed several street estimates and prompted positive analyst activity. The trades took place under an established 10b5-1 plan, with the plan set to expire in late April 2026.

Risks

  • Insider sales occurred despite strong quarterly results, which may introduce short-term market uncertainty for the MedTech and healthcare equipment sectors.
  • The 10b5-1 plan governing the director's trades is set to expire on April 28, 2026, leaving future insider activity uncertain for the near term.
  • Analyst optimism and upgraded price targets depend on execution of product rollouts and margin improvement guidance; failure to meet those expectations could affect MedTech valuations and investor sentiment.

More from Insider Trading

Planet 13 VP of Operations Sells 25,000 Shares as Company Reports Q3 Revenue and Strategic Shift Feb 2, 2026 Popular Inc. Director Sells $312,700 in Stock as Analysts Lift Targets After Strong Q4 EPS Feb 2, 2026 Robert de Rothschild Disposes $3.7M in PrimeEnergy (PNRG) Stock Over Two Days Feb 2, 2026 Elutia director buys $20,800 in Class A shares as company reports revenue gain and Nasdaq notice Feb 2, 2026 Symbotic Accounting Chief Disposes $457,722 in Shares as Company Prices 10M-Share Offering; Goldman Lowers Rating Feb 2, 2026